^
CANCER:

Lymphoplasmacytic Lymphoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1 week - (New A2)
MYD88 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
B
SOHO 2022 - 1 week - (New B)
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
acalabrutinib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
fludarabine oral
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
cladribine
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
everolimus
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
ofatumumab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
R-CHOP
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
IRd
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
FCR
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
bendamustine
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
BDR
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
BR
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
CaRD
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
RCD
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
RCP
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
venetoclax
Sensitive
:
A2
No biomarker
Lymphoplasmacytic Lymphoma
venetoclax
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
CLR 131
Sensitive
:
B
No biomarker
Lymphoplasmacytic Lymphoma
CLR 131
Sensitive
:
B
MYD88 L265P
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
B
MYD88 wild-type
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
B
CXCR4 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
B
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C2
MYD88 L265P
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
venetoclax
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
BDR
Sensitive
:
C3
MYD88 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
C3